Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Previous studies used higher doses of otelixizumab, an anti-CD3 monoclonal antibody, but also saw a reactivation of the Epstein Barr virus.
In patients with type 1 diabetes, a higher C-peptide concentration is associated with a controlled HbA1c and fewer complications. Otelixizumab is an anti-CD3 monoclonal antibody that works by upregulating T regulatory cells and downregulating pathogenic T cells. In doing so, it could inhibit the autoimmune process of this disease in which T cells destroy pancreatic β-cells responsible for insulin production.
A previous study showed positive results in using otelixizumab to preserve β-cell function in recent-onset type 1 diabetes patients. However, the dose used, 48-64mg over 6 days, was found to cause some adverse events in these patients. About 75% of patients receiving otelixizumab saw a reactivation of the Epstein Barr virus.
http://www.diabetesincontrol.com/ar...xizumab-preserve-beta-cell-function-in-type-1
In patients with type 1 diabetes, a higher C-peptide concentration is associated with a controlled HbA1c and fewer complications. Otelixizumab is an anti-CD3 monoclonal antibody that works by upregulating T regulatory cells and downregulating pathogenic T cells. In doing so, it could inhibit the autoimmune process of this disease in which T cells destroy pancreatic β-cells responsible for insulin production.
A previous study showed positive results in using otelixizumab to preserve β-cell function in recent-onset type 1 diabetes patients. However, the dose used, 48-64mg over 6 days, was found to cause some adverse events in these patients. About 75% of patients receiving otelixizumab saw a reactivation of the Epstein Barr virus.
http://www.diabetesincontrol.com/ar...xizumab-preserve-beta-cell-function-in-type-1